Company Melinta Therapeutics Inc Nasdaq
Equities
US58549G1004
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 20-08-02 | |
Susan Blum
DFI | Director of Finance/CFO | 52 | 15-12-31 |
Compliance Officer | 45 | - | |
Jisoo Park
PRN | Corporate Officer/Principal | - | 21-07-05 |
Kristen Allgor
HRO | Human Resources Officer | - | 20-11-15 |
John Harlow
PRN | Corporate Officer/Principal | - | 21-03-29 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20-04-19 |
Director/Board Member | - | 20-04-19 | |
Director/Board Member | - | 20-04-19 | |
Compliance Officer | 45 | - | |
Chief Executive Officer | 48 | 20-08-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 13,750,691 | 13,578,334 ( 98.75 %) | 0 | 98.75 % |
Company contact information
Melinta Therapeutics, Inc.
389 Interpace Parkway Suite 450
07054, Parsippany
+908-617-1300
http://melinta.com![address Melinta Therapeutics Inc](https://cdn.zonebourse.com/static/address/38588350.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |